Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Drug Watch Website Coming "Soon"

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's new drug safety website will make more information available to the public "soon," the website states as of Feb. 23

You may also be interested in...



FDA Drug Safety Website Could Cause More Harm Than Good, Novartis Says

Novartis says risk information should be communicated quickly, but that it should be validated first, to avoid confusion. Company's comments come on heels of FDA's statement that Novartis' Elidel should have a black box, a move the company describes as unsubstantiated by clinical evidence and experience.

FDA Drug Safety Website Could Cause More Harm Than Good, Novartis Says

Novartis says risk information should be communicated quickly, but that it should be validated first, to avoid confusion. Company's comments come on heels of FDA's statement that Novartis' Elidel should have a black box, a move the company describes as unsubstantiated by clinical evidence and experience.

RiskMAP Guidance Includes Plans For A Website

FDA is planning to develop a Risk Minimization Action Plan website, an agency risk management guidance states

Related Content

Topics

UsernamePublicRestriction

Register

PS061617

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel